Efficacy and Safety of Capmatinib Plus Nivolumab in Pretreated Patients with EGFR Wild-Type Non-Small Cell Lung Cancer

被引：0
|
作者：
Felip, E. [1 ]
Minotti, V. [2 ]
Tan, D. [3 ]
Wolf, J. [4 ]
Mark, M. [5 ]
Boyer, M. [6 ]
Hughes, B. [7 ,8 ]
Bearz, A. [9 ]
Moro-Sibilot, D. [10 ]
Le, X. [11 ]
Vazquez, J. [12 ]
Massuti, B. [13 ]
Liu, N. [14 ]
Hao, L. [14 ]
Cheng, Y. [14 ]
Tiedt, R. [15 ]
Cobo, M. [16 ]
机构：
[1] Vall DHebron Inst Oncol Vhio, Oncol Serv, Barcelona, Spain
[2] AO Perugia Osped S Maria Misericordia Loc S Andre, Perugia, Italy
[3] Natl Canc Ctr Singapore, Singapore, Singapore
[4] Univ Hosp Cologne, Ctr Integrated Oncol, Cologne, Germany
[5] Kantonsspital, Dept Hematol Oncol, Chur, Switzerland
[6] Chris OBrien Lifehouse, Med Oncol, Camperdown, ACT, Australia
[7] Prince Charles Hosp, Chermside, Qld, Australia
[8] Univ Queensland, Brisbane, Qld, Australia
[9] IRCCS Aviano, Aviano, Italy
[10] Ctr Hosp Univ Grenoble Alpes, Grenoble, France
[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[12] Hosp Clin Univ San Carlos, Madrid, Spain
[13] Hosp Gen Univ Alicante, Alicante, Spain
[14] Novartis Inst Biomed Res Co Ltd, Shanghai, Peoples R China
[15] Novartis Inst Biomed Res, Basel, Switzerland
[16] Hosp Univ Carlos Haya, Med Oncol Serv, Malaga, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
PD-L1; inhibitor; MET inhibitor; advanced NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.03
引用
收藏
页码：S585 / S586
页数：2
相关论文
共 50 条
  • [41] Clinical and biological significance of erlotinib therapy after pemetrexed in non-small cell lung cancer with wild-type EGFR
    Koyama, N.
    Suzuki, M.
    [J]. NEOPLASMA, 2015, 62 (06) : 996 - 1004
  • [42] Efficacy and safety of EGFR-TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations
    Wang, Jia-li
    Chen, Chuan-sheng
    Jia, Zhi-rong
    Miao, Li-yun
    Xie, Jun
    Pan, Zhen-zhen
    Duan, Ya-lei
    Liu, Shuo
    Hou, Meng-jun
    Ding, Xuan-sheng
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) : 3895 - 3903
  • [43] Efficacy and Safety of Nivolumab in Non-Small Cell Lung Cancer Patients Who Relapse after Thoracic Radiotherapy
    Yamaguchi, T.
    Oya, Y.
    Kagawa, Y.
    Furuta, H.
    Watanabe, N.
    Shimizu, J.
    Horio, Y.
    Uemura, T.
    Morikawa, S.
    Imaizumi, K.
    Hida, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2426 - S2426
  • [44] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Thomas E. Stinchcombe
    [J]. Current Treatment Options in Oncology, 2016, 17
  • [45] Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure A Nonrandomized Clinical Trial
    Zhang, Xiangyu
    Xiong, Yi
    Xia, Qing
    Wu, Fang
    Liu, Lingli
    Zhou, Yuling
    Zeng, Liang
    Zhou, Chunhua
    Xia, Chen
    Jiang, Wenjuan
    Liao, Dehua
    Xiao, Lili
    Liu, Li
    Yang, Haiyan
    Guan, Rui
    Li, Kunyan
    Wang, Jing
    Lei, Guang
    Zhang, Yongchang
    Yang, Nong
    [J]. JAMA NETWORK OPEN, 2020, 3 (03)
  • [46] Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer
    Yamaguchi, Ou
    Imai, Hisao
    Minemura, Hiroyuki
    Suzuki, Kensuke
    Wasamoto, Satoshi
    Umeda, Yukihiro
    Osaki, Takashi
    Kasahara, Norimitsu
    Uchino, Junji
    Sugiyama, Tomohide
    Ishihara, Shinichi
    Ishii, Hisashi
    Naruse, Ichiro
    Mori, Keita
    Kotake, Mie
    Kanazawa, Kenya
    Minato, Koichi
    Kagamu, Hiroshi
    Kaira, Kyoichi
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (04) : 761 - 771
  • [47] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Stinchcombe, Thomas E.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (04)
  • [48] Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer
    Ou Yamaguchi
    Hisao Imai
    Hiroyuki Minemura
    Kensuke Suzuki
    Satoshi Wasamoto
    Yukihiro Umeda
    Takashi Osaki
    Norimitsu Kasahara
    Junji Uchino
    Tomohide Sugiyama
    Shinichi Ishihara
    Hisashi Ishii
    Ichiro Naruse
    Keita Mori
    Mie Kotake
    Kenya Kanazawa
    Koichi Minato
    Hiroshi Kagamu
    Kyoichi Kaira
    [J]. Cancer Chemotherapy and Pharmacology, 2020, 85 : 761 - 771
  • [49] The Efficacy and Safety of Nivolumab, Pembrolizumab, and Atezolizumab in Treatment of Advanced Non-small Cell Lung Cancer
    Chen, Rui
    Tao, Yuquan
    Xu, Xin
    Shan, Liang
    Jiang, Hongyuan
    Yin, Qilei
    Pei, Lingyan
    Cai, Feng
    Ma, Lifang
    Yu, Yongchun
    [J]. DISCOVERY MEDICINE, 2018, 26 (143) : 155 - 166
  • [50] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S980 - S981
12345